Compare Heron Therapeutics Inc (HRTX) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Microsoft — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Microsoft trades at $523.86 (market cap $3.93T). The key difference: Microsoft is far larger — about 53079.4× Heron Therapeutics Inc's market cap, and Microsoft pays a 0.74% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Microsoft for 142 Days on average.
| HRTX | MSFT | |
|---|---|---|
Market Cap | $74.04M | $3.93T |
Volume | 3,668,095 | 16,040,951 |
Sector | Health | Technology |
52-Week High | $1.49 | $542.07 |
52-Week Low | $0.27 | $352.83 |
Typical Hold Time | 35 Days | 142 Days |
Enterprise Value | $180.78M | $3.91T |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Microsoft (MSFT) trades at $522.61, down 1.26% on the day, amid a bullish technical setup with strong moving average signals and key support at $522. The company reported robust fundamentals with Q2 2026 EPS of $4.74 beating estimates, revenue growth to $281.72B in 2025, and net income margins of 40.31%. Recent news highlights AI leadership and Azure momentum, though RSI levels suggest overbought conditions.
Outlook remains positive with an 81.71% analyst buy rating and a $571.76 consensus price target, implying ~9% upside. Risks include elevated capital expenditure concerns and competitive pressures in AI. Strong cash flow generation and a declining debt-to-asset ratio support long-term growth, but investors should monitor execution on AI investments and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
